China’s National Medical Products Administration (NMPA) said in its latest drug sampling notice that 27 batches of medicines labelled as manufactured by 17 pharmaceutical companies, including Beijing Tong Ren Tang, failed to meet regulatory standards. Drug regulators have ordered the companies concerned to suspend sales and use of the affected products and recall them, among other measures. They have also instructed the relevant authorities to open investigations into suspected legal violations by the companies and entities involved.

CCTV News reported on Tuesday (17 November), citing the NMPA, that the regulator’s latest drug sampling notice identified 27 batches of medicines that failed to meet regulatory standards following testing by seven drug testing institutions, including the Tianjin Institute for Drug Control. The medicines were labelled as manufactured by 17 pharmaceutical companies, including the Tong Ren Tang Pharmaceutical Factory of Beijing Tong Ren Tang Co Ltd. The batches fell short of China’s regulatory requirements on indicators including moisture content, the presence of visible foreign matter, and the rate and extent of dissolution of active pharmaceutical ingredients.

Among them, one batch of Yinianjin, labelled as manufactured by the Tong Ren Tang Pharmaceutical Factory of Beijing Tong Ren Tang Co Ltd, failed to meet requirements for moisture content — the amount of water in the medicine. Beijing Tong Ren Tang is a well-known traditional Chinese medicine brand in China.

Visible foreign matter was also found in four batches of gatifloxacin eye drops labelled as manufactured by Zhengzhou Zhuofeng Pharmaceutical Co Ltd and Chuxiong Laoboyuntang Pharmaceutical Co Ltd.

The NMPA said drug regulators had ordered the companies and entities concerned to take risk-control measures, including suspending sales and use of the affected products and recalling them, as well as investigating the causes and taking effective corrective action. It also instructed the relevant provincial drug regulators to open investigations into suspected legal violations by the companies and entities involved, and to publish the findings and enforcement outcomes as required.